NCT00614055 - Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

178

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec/insulin aspart

Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily

DRUG

insulin degludec/insulin aspart

Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily

DRUG

insulin glargine

Treat-to-target dose titration scheme, injection s.c., once daily

DRUG

metformin

Tablets, 1500-2000 mg/day

Trial Locations (28)

2212

Novo Nordisk Investigational Site, Kongsvinger

2317

Novo Nordisk Investigational Site, Hamar

2408

Novo Nordisk Investigational Site, Elverum

4011

Novo Nordisk Investigational Site, Stavanger

9038

Novo Nordisk Investigational Site, Tromsø

17019

Novo Nordisk Investigational Site, La Rochelle

29609

Novo Nordisk Investigational Site, Brest

30100

Novo Nordisk Investigational Site, Alès

40024

Novo Nordisk Investigational Site, Mont-de-Marsan

41010

Novo Nordisk Investigational Site, Seville

41460

Novo Nordisk Investigational Site, Neuss

41539

Novo Nordisk Investigational Site, Dormagen

46014

Novo Nordisk Investigational Site, Valencia

47011

Novo Nordisk Investigational Site, Valladolid

55545

Novo Nordisk Investigational Site, Bad Kreuznach

56564

Novo Nordisk Investigational Site, Neuwied

69200

Novo Nordisk Investigational Site, Vénissieux

71200

Novo Nordisk Investigational Site, Le Creusot

97980

Novo Nordisk Investigational Site, Bad Mergentheim

06679

Novo Nordisk Investigational Site, Hohenmölsen